Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, multicentre, randomised, double-blind, placebo-controlled study with open-label follow on, to evaluate the efficacy, safety and tolerability of PSD502 [lidocaine/prilocaine] in subjects with Premature Ejaculation (PE)

Next Previous
Trial Profile

A phase III, multicentre, randomised, double-blind, placebo-controlled study with open-label follow on, to evaluate the efficacy, safety and tolerability of PSD502 [lidocaine/prilocaine] in subjects with Premature Ejaculation (PE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine/prilocaine (Primary)
  • Indications Premature ejaculation
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 23 Sep 2013 Positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP), recommending EC approval for lidocaine/prilocaine, according to a Plethora Solutions Holdings media release.
  • 03 Jun 2010 Retrospective analysis reported at 105th Annual Meeting of the American Urological Association.
  • 03 Jun 2010 A pooled analysis of this and another pivotal phase III (700030634) trial has been presented at the 105th Annual Meeting of the American Urological Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top